Report of Foreign Issuer (6-k)
August 07 2017 - 8:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the month of August 2017
Commission File Number: 001-37569
STRONGBRIDGE BIOPHARMA plc
(Exact name of Registrant as specified in its charter)
900 Northbrook Drive
Suite 200
Trevose, PA 19053
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
On August 7, 2017, Strongbridge Biopharma plc (the
Registrant
) issued a press release providing certain updates and business highlights, as well as second quarter 2017 financial results.
The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrants registration statements or other filings with the Commission.
Exhibits
Exhibit
Number
|
|
Exhibit Table
|
99.1
|
|
Press Release issued by Strongbridge Biopharma plc, dated August 7, 2017.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: August 7, 2017
|
STRONGBRIDGE BIOPHARMA PLC
|
|
|
|
|
|
By:
|
/s/ Stephen Long
|
|
|
Stephen Long
|
|
|
Chief Legal Officer
|
3
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Sep 2023 to Sep 2024